Lilly pays $2.8bn for AtaiBeckley in psychedelic M&A push

Eli Lilly agreed to buy psychedelic drugmaker AtaiBeckley for $2.8 billion in cash, placing a significant bet on a new class of mental health treatments. The $6.75 per share offer represents a 26% premium to Wednesday’s closing price of $5.36. AtaiBeckley shares spiked more than 30% in premarket trading following the announcement.

The transaction immediately grants Lilly access to BPL-003, an experimental DMT-based nasal spray currently in Phase 3 clinical trials for treatment-resistant depression. The treatment requires patients to be administered the drug in a clinical setting where they are monitored for approximately two hours. Because the drug is still in late-stage testing, initial Phase 3 results are not expected until 2029.

In addition to the DMT-based treatment, AtaiBeckley is advancing a broader pipeline of psychedelic compounds. This includes an early-stage program related to MDMA, commonly known as ecstasy, which targets various mental health conditions. For Lilly, acquiring this pipeline provides a foothold in a therapeutic area that has traditionally been dominated by smaller, venture-backed biotechs rather than large pharmaceutical manufacturers.

The acquisition reflects a broader shift in the regulatory and political landscape surrounding psychedelics. The Trump administration has explicitly prioritized the development of psychedelic-based treatments for mental health conditions, including depression and post-traumatic stress disorder. This political backing has helped reduce the perceived regulatory risk that previously deterred major pharmaceutical companies from entering the space.

For investors, the deal is notable less for its scientific novelty and more for what it signals about Lilly's evolving capital allocation strategy. The company has deliberately shifted away from the early-stage, lower-cost deals that historically defined its acquisition approach. Now operating as the world's most valuable healthcare company, Lilly is deploying its massive market valuation to secure later-stage, higher-priced assets that carry lower clinical risk but require substantial upfront capital.

The AtaiBeckley purchase is the latest addition to an aggressive buying spree. Including this transaction, Lilly has now announced nine acquisitions this year. The company had previously stated it would spend more than $10 billion in upfront payments across these deals.

The total financial exposure for Lilly could ultimately reach $25 billion. Under the terms of the AtaiBeckley agreement, Lilly could pay an additional $2.50 per share, or roughly $1 billion, if the drugmaker hits specific development and regulatory milestones. This structure allows Lilly to manage its immediate capital outlay while retaining exposure to the upside if the psychedelic treatments successfully reach the market.